Trimtech lands $31m to combat neurodegenerative diseases with targeted protein degradation

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Pfizer and Lilly join investors in biotech seeking to selectively degrade harmful protein aggregates without affecting essential monomers.

British biotech Trimtech Therapeutics has secured $31 million in seed funding to advance its pipeline of targeted protein degradation therapies for neurodegenerative and inflammatory diseases. The investment will enable the company to further develop its proprietary aggregate-selective degraders, a class of CNS-penetrant therapeutics designed to address diseases such as Alzheimer’s and Huntington’s.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE